In 1981, a phase II study confirmed single-agent cisplatin 50 mg/m 2 administered every 3 weeks as the standard therapeutic regimen for patients with cervical cancer. 2 In this trial, the response ...
The addition of concurrent cisplatin to adjuvant radiation therapy conferred no benefit to women with intermediate-risk, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback